Shares of Tectonic Therapeutic Inc. (NASDAQ: TECX) plunged 5.44% on Wednesday morning after the clinical-stage biotech company reported a wider-than-expected loss for the third quarter of 2024.
Tectonic reported an adjusted loss per share of $1.20 for Q3, missing consensus analyst estimates of $0.82 loss per share. The company's GAAP net loss of $17.72 million was also larger than the prior year's Q3 loss of $5.28 per share.
The disappointing results appear to have triggered a sell-off in Tectonic's stock, which had rallied 48% over the past quarter and nearly 175% year-to-date heading into the earnings release. With no revenue yet as a development-stage biotech firm, Tectonic's valuation is highly sensitive to changes in cash burn rates and missed earnings expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.